FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 Patients – The New York Times

ZURICH– The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to check RLF-100 (aviptadil) for inhaled usage in clients with moderate and extreme COVID-19 to prevent progression to breathing failure, it and partner Relief Therapeutics Holdings stated on Thursday.
The clinical trial of the inhaled formulation of RLF-100 is expected to start on or prior to Sept. 1, a joint statement stated.
They said aviptadil is shown as the very first COVID therapeutic to obstruct duplication of the SARS-CoV-2 virus in human lung cells and monocytes while likewise avoiding synthesis of cytokines in the lung. It is a trademarked formula of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has actually been given FDA fast track classification, FDA emergency situation use IND authorisation, and an expanded access protocol.
( Reporting by Michael Shields; modifying by Thomas Seythal).